

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup>:</b> <b>C12N 15/82, 15/60, 5/10</b> <b>A01H 1/02, 5/00</b>	<b>(11) International Publication Number:</b> <b>WO 93/06220</b> <b>(43) International Publication Date:</b> 1 April 1993 (01.04.93) <b>A1</b>
<b>(21) International Application Number:</b> PCT/EP92/02175 <b>(22) International Filing Date:</b> 18 September 1992 (18.09.92) <b>(30) Priority data:</b> 91202458.5 20 September 1991 (20.09.91) EP <i>(34) Countries for which the regional or international application was filed:</i> NL et al. <b>(71) Applicant (for all designated States except US):</b> MOGEN INTERNATIONAL N.V. [NL/NL]; Einsteinweg 97, NL-2333 CB Leiden (NL). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HOGE, Johan, Herman, Carolus [NL/NL]; Zeeforel 16, NL-2318 MP Leiden (NL). GODDIJN, Oscar, Johannes, Maria [NL/NL]; Emilie Knapperhof 6, NL-2312 MZ Leiden (NL). SCHILPEROORT, Robbert, Adriaan [NL/NL]; Anthonie Duycklaan 10 c, NL-2334 CD Leiden (NL).	<b>(74) Agents:</b> HUYGENS, Arthur, Victor et al.; Gist-Brocades N.V., Patents and Trademarks Department, Wateringseweg 1, P.O. Box 1, NL-2600 MA Delft (NL). <b>(81) Designated States:</b> AU, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TRYPTOPHAN ANALOGUES AS SELECTIVE AGENTS IN THE TRANSFORMATION OF PLANTS AND PLANT CELLS  <b>(57) Abstract</b>  The instant invention provides a method for the selection of transformed plant cells, comprising the steps of: i) transforming plant cells with a polynucleotide sequence comprising a plant expressible gene encoding a tryptophan analogue converting activity, ii) culturing said plant cells, or growing plant material comprising said plant cells, in the presence of a selective amount of a tryptophan analogue deleterious to non-transformed plant cells, under conditions that allow for the manifestation of said deleterious effect.	

**BEST AVAILABLE COPY**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	MI	Mali	UA	Ukraine
ES	Spain			US	United States of America

5                   Tryptophan analogues as selective agents in the  
                    transformation of plants and plant cells

TECHNICAL FIELD

                    The present invention is related to the selection of transformed plant cells or plants. The invention also  
10 comprises plants obtained by the said method as well as DNA sequences useful therein.

BACKGROUND OF THE INVENTION

                    In the process of introducing a useful property into  
15 plants or plant cells by genetic engineering, it has proven almost unavoidable to make use of a selection marker. This necessity is partly related to the fact that many valuable properties can not be readily observed during the transformation process and the fact that transformation  
20 frequencies are still rather low.

                    If the marker gene and the DNA sequence of interest providing the useful property are located on the same transforming polynucleotide sequence the introduction of the marker gene is likely to coincide with the introduction of  
25 the gene of interest. Hence, a first selection for cells that contain and express the marker will generally reduce the number of cells that have to be analysed for the presence and expression of the gene of interest. Obviously, this saves laboratory space, working hours and reduces costs  
30 considerably; in many cases, especially with the more difficult crops, transformation without selection is not feasible at all.

                    Among the marker genes that are most widely used in plant transformation are the bacterial neomycin phosphotransferase  
35 genes (nptI, nptII and nptIII genes) conferring resistance to the selective agent kanamycin, disclosed in EP-B 131 623, and the the bacterial aphIV gene, disclosed in EP-A 186 425 conferring resistance to hygromycin.

                    These markers are not suitable for selection of  
40 transformants of all plant species; some plant species appear to be naturally resistant against the selective agents used

herein (Waldron, C. et al., (1985) Plant Molecular Biology 5, 103-108; Van den Elzen, P.J.M. et al., (1985) Plant Molecular Biology 5, 299-302).

Eukaryotic genes are also known to be used as selection  
5 markers in plants. EP-A 256 223 discloses a Glutathion-S-transferase gene from rat liver, conferring resistance to glutathion derived herbicides.

Overproduction of yeast glutamin synthetase confers resistance to glutamine synthetase inhibitors such as  
10 phosphinotricin, as disclosed in WO87/05327.

EP-A 275 957 discloses the use of an acetyl transferase gene from Streptomyces viridochromogenes that confers resistance to the selective agent phosphinotricin.

Plant genes conferring relative resistance to the  
15 herbicide Glyphosate are disclosed in EP-A 218 571. The resistance is based on the expression of a gene encoding a 5-enolshikimate-3-phosphate synthase (EPSPS) that is relatively tolerant to N-phosphonomethylglycine. The selective compound is not converted by EPSPS.

20 In spite of the existence of a number of selectable marker genes that are suitable for plant species there is still a need for other selectable marker genes.

#### STATE OF THE ART

25 Tryptophan analogues have been used to screen for Catharanthus roseus cells with a high endogenous tryptophan decarboxylase (TDC) activity (Sasse F. et al., (1983) Z. Naturforschung 38c, 910-915). The analogues with the most growth inhibitory activity were identified as 4-methyl-, 4-  
30 fluoro-, 5-fluoro-, and 5-hydroxy-tryptophan. Cultured Catharanthus cells with increased resistance to 4-mT contained increased levels of TDC. Therefore, the authors assumed that it should be possible to devise selection schemes for establishing plant cell cultures with higher  
35 activities of detoxifying enzymes with the purpose of obtaining strains with the capacity to produce increased levels of useful secondary metabolites.

The complete DNA sequence of a cDNA encoding the tryptophan decarboxylase (EC 4.1.1.28, formerly 4.1.1.27) of Catharanthus roseus has been disclosed (De Luca V. et al., (1989) Proc. Natl. Acad. Sci. USA 86, 2582-2586). The cDNA  
5 encodes a protein of 500 amino acids. It was shown that this cDNA can be expressed in transgenic tobacco plants under the control of the CaMV 35S promoter (Songstad et al., (1990) Plant Physiol. 94, 1410-1413). Transgenic tobacco plants showed up to 260 times increased tryptamin levels due to the  
10 conversion of endogenous tryptophan. These plants seemed phenotypically normal. This suggests that plants expressing increased levels of TDC may be useful for producing (increased levels of) commercially important antineoplastic monoterpenoid indole alkaloids, vinblastine and vincristine,  
15 as suggested in International Patent Application, WO90/10073 published on 7 September 1990.

Tryptophan analogues have never been used for the selection in the process of transforming plant cells and plants. The use of a plant expressible TDC gene as a  
20 selectable marker gene in a process of transforming plants has not been disclosed.

#### SUMMARY OF THE INVENTION

The invention provides a method for the selection of  
25 transformed plant cells comprising the steps of  
i) transforming plant cells with a recombinant polynucleotide comprising a plant expressible gene encoding a tryptophan analogue converting activity,  
ii) culturing said plant cells, or growing plant material  
30 comprising said plant cells, in the presence of a selective amount of a tryptophan analogue deleterious to non-transformed plant cells, under conditions that allow for the manifestation of said deleterious effect.

A preferred plant expressible gene is one encoding  
35 tryptophan tryptophan decarboxylase. Still further preferred is a tryptophan decarboxylase gene from Catharanthus roseus or a functional derivative thereof. Most preferred is a plant

expressible decarboxylase gene under the control of the CamV 35S promoter.

According to a preferred embodiment of the invention the said recombinant polynucleotide further comprises a polynucleotide sequence of interest which is a plant expressible gene giving rise to fungal resistance, insect resistance, nematode resistance, virus resistance, altered carbohydrate composition, altered oil composition, altered amino acid composition, male-sterility, modified flower color, modified fruit ripening, salt resistance, herbicide resistance, antibiotic resistance, production of a secondary metabolite, production of a pharmaceutical protein, or production of enzymes useful in an industrial process.

Preferred for use as selective agents in a method according to the invention are tryptophan analogues selected from the group consisting of 4-methyltryptophan (4-mT), 5-methyltryptophan (5-mT), 4-fluorotryptophan (4-fT) and 5-hydroxytryptophan (5-hT).

The invention also comprises plant cells obtained by a method according to the invention, as well as plant material and plants harbouring such cells. Preferred plant parts are those selected from the group consisting of bulbs, flowers, fruits, hairy roots, leaves, microtubers, pollen, roots, seeds, stalks and tubers.

A further embodiment of the invention comprises the use of a tryptophan analogue according to the invention for the selection of a transformed plant cell.

Yet another aspect of the invention comprises the use of a plant expressible gene encoding an enzyme having a tryptophan analogue converting activity as a marker gene for the selection of transformed plant cells.

The invention further comprises a method for obtaining a transformed plant comprising the steps of:

- i) transforming plant cells with a polynucleotide sequence comprising a plant expressible gene encoding a tryptophan analogue converting activity,
- ii) culturing said plant cells, or growing plant material

comprising said plant cells, in the presence of a selective amount of a tryptophan analogue deleterious to non-transformed plant cells, under conditions that allow for the manifestation of said deleterious effect,

- 5   iii) regenerating surviving cells of step ii) into a plant,  
iv) identifying a transformed plant.

Preferred in this method is a plant expressible gene encoding a tryptophan analogue converting activity is a plant expressible tryptophan decarboxylase gene. Still more  
10 preferred in the method is a tryptophan decarboxylase gene from Catharanthus roseus or a functional derivative thereof. In a still further preferred embodiment the tdc gene is under the control of the CaMV 35S promoter.

In a highly preferred embodiment said recombinant  
15 polynucleotide further comprises a polynucleotide sequence of interest. More preferably said polynucleotide sequence of interest is a plant expressible gene which gives rise to fungal resistance, insect resistance, nematode resistance, virus resistance, altered carbohydrate composition, altered  
20 oil composition, altered amino acid composition, male-sterility, modified flower color, modified fruit ripening, salt resistance, herbicide resistance, antibiotic resistance, production of a secondary metabolite, production of a pharmaceutical protein or production of an industrial enzyme.

25       Another embodiment of the invention is a plant obtained with a method according to the invention, as well as progeny plants obtained after sexually or asexually propagating said plants.

The invention also comprises a product obtained  
30 after the processing of a plant part of plants obtained with a method according to the invention.

Another aspect of the invention is a recombinant polynucleotide which can be used for the transformation of plant cells and subsequent selection of transformed plant  
35 cells, comprising a plant expressible gene encoding a tryptophan analogue converting activity. Another embodiment of the invention comprises said recombinant polynucleotide

which further comprises a polynucleotide sequence of interest, with the proviso that said polynucleotide sequence of interest is not a plant expressible nptII gene. Still further preferred is a recombinant polynucleotide with the proviso that said polynucleotide sequence of interest is not known as a selectable marker gene for use in the transformation of plants. A preferred recombinant polynucleotide according to the invention is one wherein the polynucleotide sequence of interest comprises a plant expressible gene which gives rise to fungal resistance, insect resistance, nematode resistance, virus resistance, altered carbohydrate composition, altered oil composition, altered amino acid composition, male-sterility, modified flower color, modified fruit ripening, salt resistance, production of a secondary metabolite, production of a pharmaceutical protein or production of an industrial enzyme.

A different aspect of the invention comprises a recombinant plant DNA genome containing a copy of a recombinant polynucleotide according to the invention, as well as plants or plant cells containing such recombinant plant DNA genome.

The invention also comprises a substantially pure DNA molecule which comprises the nucleotide sequence represented in SEQIDNO: 2.

The advantages and the field of application will be readily appreciated from the following detailed description of the invention.

#### DESCRIPTION OF THE FIGURES

The following figures further illustrate the invention.

Figure 1: A diagrammatic representation of the cloning steps resulting in the binary vector pBDH5, containing the nptII gene under control of the Nos promoter and terminator; the binary vector pTDCs containing the nptII gene and the tdc sense construct; the binary vector pTDCa



- 7 -

containing the nptII gene and the tdc antisense construct;

Figure 2: Northern blot: Analysis of tdc transcript levels in transgenic Nicotiana tabacum plants obtained after leaf-disc transformation with LBA 4404 containing pBDH5 (vector), pTDCa (antisense), or pTDCs (sense) constructs. The blot was hybridised with <sup>32</sup>P dCTP labelled tdc cDNA: A - J represent different independent lines harbouring either the sense constructs (SENSE A - J), the antisense constructs (ANTISENSE A - D) or the 'empty' vector pBDH5 (VECTOR A - B). SENSE constructs were classified as low (A, G), intermediate (B, C, D, F) or high expressors (E, H, I, J).

Figure 3: Leaf-discs of pTDCs transgenic N. tabacum plants cultured on shooting medium containing 0, 0.05, 0.10, 0.50 or 1.00 mM 4-methyl tryptophan. Leaf explants were used from tobacco plants A, C and I containing respectively low (sense: L), intermediate (sense: M) and high (sense: H) tdc transcript levels. As a control, leaf explants from a pBDH5 (vector) transformed plant were used.

Figure 4: Leaf-discs of N. tabacum treated with LBA 4404 containing pTDCs (sense), pTDCa (antisense), pBDH5 (vector) and leaf-discs not treated with Agrobacterium (- Agrob). Selection was performed on 0.1 mM 4-methyl tryptophan.

Figure 5: Northern blot: tdc and nptII transcript levels in transgenic plants obtained after leaf-disc transformation with LBA 4404 containing pTDCs

(sense) and subsequent selection on 0.1 mM 4-methyl tryptophan.

#### DETAILED DESCRIPTION OF THE INVENTION

- 5 The present invention discloses a method for the selection of transformed plant cells, comprising the steps of:
- i) transforming plant cells with a polynucleotide sequence comprising a plant expressible gene encoding a tryptophan analogue converting activity,
  - 10 ii) culturing said plant cells, or growing plant material comprising said plant cells, in the presence of a selective amount of a tryptophan analogue deleterious to non-transformed plant cells, under conditions that allow for the manifestation of said deleterious effect. The various aspects
  - 15 of the invention are further clarified below. Such aspects concern 1) the plant expressible marker gene, 2) the selection conditions, 3) the plant material to be transformed 4) transformation of plant material with the said polynucleotide sequence 5) the polynucleotide sequence of
  - 20 interest.

For a better understanding of the various ways of practicing the invention a number of these aspects will be outlined in more detail below. The enumeration is not meant to be limitative with respect to ways of carrying out the

25 invention, its applicability or in any other way.

Whenever the expression 'tryptophan analogue' is used reference is made to tryptophan itself or a compound having a alkyl-, hydroxyl-, halo-, aryl-, aryloxy-, alkoxy-, or aza-group in the position 1, 4, 5, 6, or 7, or any combination of

30 two or more of such groups.

- 1) the plant expressible marker gene

The expression 'plant expressible marker gene' refers to a polynucleotide sequence comprising the marker

35 gene as well as the regulatory sequences required for expression of the marker gene in the plant cell.

Suitable marker genes that fall within the scope of the

- 9 -

invention are those which encode an enzyme having the capacity to convert a tryptophan analogue according to the invention into a different analogue with a less toxic effect on the plant cell. Such enzymes are not limited to  
5 decarboxylases; any other enzymatic activity having the capacity to convert a toxic tryptophan analogue are useful as long as the conversion results in detoxification of the said tryptophan analogue.

The word 'gene' as used here is meant to comprise cDNAs as  
10 well as genomic clones, as well as synthetic or partially synthetic analogues thereof that encode a protein; they may be derived from procaryotes and eucaryotes alike.

The regulatory sequences may include promoters and so-called enhancers, which may drive expression constitutively  
15 or developmentally and/or environmentally regulated. Many promoters that are generally suitable for the expression of genes in plants are described in the prior art. In order to be useful to drive expression of the marker gene according to the invention it is necessary that the promoter is functional  
20 in the plant cell during application of selection pressure. Therefore, promoters generally regarded as constitutive are preferred, such as the CaMV 19S promoter and the CaMV 35S promoter, or the promoters derivable from the T-DNA of Ti-plasmids from Agrobacterium, although any other homologous or  
25 heterologous promoter that meets the requirements set out above may be used. It will be understood by those skilled in the art that promoters obtainable from endogenous plant genes are suitable as well.

The selectable marker gene will generally comprise a so-called terminator sequence, including a polyadenylation  
30 signal, for proper expression of the marker gene. Said terminator may be homologous or heterologous to the said gene. Sources of suitable terminators sequences are well known to those of skill in the art.

35

2) the selection conditions

The selection conditions may vary depending on for

instance the choice of the tryptophan analogue and the choice of the plant material used.

Obviously, tryptophan analogues that are less toxic to a particular plant cell may need a higher concentration to obtain an effective selection of a transformed cell, whereas those that are more toxic require a lower concentration. Likewise a higher concentration of the tryptophan analogue may be used if the plant material to be transformed is less susceptible to the analogue, or if it is obtained from a plant already showing some degree of tryptophan analogue converting activity.

An amount of a tryptophan analogue is said to be selective if it is capable of reducing the increase of fresh weight of plant cells as compared to the increase of fresh weight in medium to which no tryptophan analogue has been added. Preferably, the selective amount of the tryptophan analogue effectively kills all non-transformed cells while transformed cells are not affected at all. In practice such a situation will rarely exist and for each type of plant material the optimal conditions have to be determined in which the increase of fresh weight of non-transformed plant material is inhibited as much as possible while the toxic effect to transformed cells remains within acceptable limits. Obviously, when transformed cells should give rise to whole plants, the regenerative capacity of the cells must not be affected by the concentration of the selective agent used.

Tryptophan analogues which have a toxic effect on plant cell growth are inter alia L-tryptophan, D-tryptophan,  $\alpha$ -methyltryptophan, N-methyl-L-tryptophan, 1-methyltryptophan, 4-methyltryptophan, 5-methyltryptophan, 6-methyltryptophan, 4-fluorotryptophan, 5-fluorotryptophan, 6-fluorotryptophan, 5-hydroxytryptophan, 5-methoxytryptophan, 5-benzyloxytryptophan and 7-azatryptophan. Whether or not a tryptophan analogue can in fact be converted by TDC from Catharanthus roseus can be determined by a number of techniques, the choice of which is not crucial to the invention; one such method is disclosed by Sasse et al.,

(1983), supra. If the tryptophan analogue is found to be converted by TDC the tdc gene from Catharanthus roseus can be used as marker gene. If desired a tryptophan decarboxylase gene may be used from another plant or even from non-plant origin as long as it encodes a tryptophan decarboxylase capable of converting and (partly) detoxifying the used tryptophan analogue. Different plant species may produce a tryptophan decarboxylase with a different substrate specificity as compared to the TDC from Catharanthus roseus.

5  
10 If desired, an enzymatic activity different from a decarboxylase may be selected, as long as the tryptophan analogue is converted into a non- or less toxic compound. A gene encoding the said enzymatic activity can be used as selection gene using a tryptophan analogue that can be  
15 converted by the said enzymatic activity.

Especially preferred as selective agent is the tryptophan analogue 4-methyltryptophan, preferably in a concentration range between 0.1 and 0.5 mM. More preferably, said selective agent is used in combination with a tryptophan decarboxylase  
20 gene as marker gene. Most preferably said tryptophan decarboxylase gene is a tdc gene derived from Catharanthus roseus.

Determination of the optimal conditions such as the selective amount and stage of exposure for each tryptophan  
25 analogue or plant material used should be well within the skill of the average worker in the area of technology to which this invention pertains.

### 3) The plant material to be transformed

30 For the purpose of this invention the expression 'plant' is not limited to species used in agriculture, floriculture or horticulture, but also includes such species used in activities such as gardening, forestry and the like.

The plant material used in the transformation process may  
35 vary due to inter alia the plant species to be transformed, the method of transformation, the nature of the plant material, such as protoplasts, cultured cells, pollen, leaf

tissue, embryonic tissue and the like, origin of the plant material, e.g. monocotyledonous or dicotyledonous plants, the necessity and the capacity of regenerating the plant material in a full grown transformed plant and the like. For each  
5 plant material the sensitivity to a particular tryptophan analogue may be determined by making a so-called killer curve; the optimal tryptophan analogue may be selected by comparing different analogues at a fixed concentration and subsequently selecting the optimal analogue. The optimal  
10 concentration of the analogue of choice may be determined by testing a concentration range, optionally in different stages of the selection process.

4) transformation of plant material with the said  
15 polynucleotide sequence

The expression transformation with a polynucleotide sequence refers to the various ways of introducing a recombinant polynucleotide directly or indirectly into a plant cell to the effect that uptake of the polynucleotide  
20 sequence by the said plant cell is achieved, whereby the genotype of said plant cell is modified. Transformation regularly involves the exposure of plant cells in culture, or more or less organised in a a tissue or callus phase, by incubating cells or tissue with so-called 'naked'  
25 polynucleotide sequences, bombardment of cells or tissue with microprojectiles carrying the polynucleotide sequence, microinjecting a solution containing the polynucleotide sequence into cells or tissue, incubating or contacting a plant cell or tissue with bacteria or viruses capable of  
30 transferring a polynucleotide sequence to the plant and the like.

Transformation methods that may be used include but are not limited to the calcium/polyethylene glycol method for protoplasts (Krens, F.A. et al., 1982, Nature 296, 72-74;  
35 Negrutiu I. et al., June 1987, Plant Mol. Biol., 10-19), electroporation of protoplasts (Shillito R.D. et al., 1985 Bio/Technology 3, 1099-1102), microinjection into plant

- 13 -

material (Crossway A. et al., 1986, Mol. Gen. Genet. 202, 179-185), (DNA or RNA-coated) particle bombardment of various plant material (Klein T.M. et al., 1987, Nature 327, 70), infection with viruses and the like.

- 5 In a preferred embodiment of the invention use is made of Agrobacterium-mediated DNA transfer. Especially preferred is the use of the so-called binary vector technology as disclosed in EP-A 120 516 and U.S. Patent 4,940,838).

After administering the transforming polynucleotide(s) to  
10 the plant material using any of the above methods, transformed cells obtained and selected according to the invention may be used as such, for instance for the production of a pharmaceutical compound in cell suspension cultures. Transformed plant cells may also be used to  
15 generate a whole new plant. The available method is itself not critical to the invention as long as uptake of the administered genetic material into the plant cell and integration of (a copy) of the genetic material into the genome of the plant cell is obtained, and the said plant  
20 material is amenable to regeneration into a whole new plant. The choice of the technique will depend on the particular type of plant material used, and the preference of the skilled worker.

Especially preferred as plant material are leaf-discs  
25 which can be readily transformed and have good regenerative capability (Horsch R.B. et al., (1985) Science 227, 1229-1231).

The use of the marker gene according to the invention is not limited to any particular transformation or regeneration  
30 method, although the optimal conditions may have to be determined for each different method used.

5) the polynucleotide sequence of interest

Often the polynucleotide sequence of interest comprises a  
35 gene encoding a protein, and the necessary regulatory sequences such that upon expression of the gene the protein is produced in a plant or plant cell at the desired stage and

at the desired site in the plant. The polynucleotide sequence of interest may also comprise genes which can be expressed in the form of an RNA sequence which does not encode protein, such as antisense genes, ribozyme genes and the like. The polynucleotide sequence of interest not necessarily needs to be capable of being transcribed; it may as well be a recognition sequence that can be recognized by proteins, e.g. a recombinase, a nuclease and the like, or by man, serving as a genetic label.

More specific examples of plant expressible genes of interest include, but are not limited to, those that give rise to fungal resistance (International Patent Application WO90/07001; EP-A 440 304), insect resistance (EP-A 159 884), nematode resistance (EP-A 352 052), virus resistance (EP-A 223 452), altered carbohydrate composition (WO90/12876; EP-A 438 904), altered oil composition (EP-A 225 377), seed storage proteins with altered amino acid composition (EP-A 208 418), male sterility (EP-A 329 308), modified flower color (EP-A 335 451), delayed fruit ripening (WO91/01375), salt resistance (WO91/06651), herbicide resistance (EP-A 218 571; EP-A 369 637), production of pharmaceutical products (EP-A 436 003), production of enzymes that can be used in industrial processes and the like.

Usually the process of transformation is eventually followed by identifying the cells having obtained the functional polynucleotide sequence.

The identification of cells having obtained the functional polynucleotide sequence can be done in several ways depending on the inherent property of the functional polynucleotide sequence. If the functional polynucleotide sequence is not expressed in the form of a RNA sequence or a protein an evaluation of the presence of the functional polynucleotide sequence may be done using a hybridisation technique; e.g. Southern blotting, or PCR analysis on genomic DNA. If the functional polynucleotide sequence is expressed in the form of an RNA molecule the presence of such molecule may be determined using inter alia a hybridisation technique



- 15 -

referred to as Northern blotting. If the functional polynucleotide sequence is expressed in the form of a protein a technique referred to as Western blotting can be used. If the protein has an enzymatic activity its presence may be analysed using an enzyme test. In some cases the presence of the polynucleotide sequence of interest need not be analysed on the molecular level, but may be concluded from the phenotype of the transformed plant; e.g. enhanced disease resistance, altered flower color, male-sterility, herbicide resistance, and the like. In the case of herbicide resistance the presence of the polynucleotide sequence of interest can, if desired, be selected for.

The findings that led to the present invention are outlined below for purposes of illustration.

15 A binary vector was constructed containing a tdc cDNA from Catharanthus roseus under control of the CaMV 35S promoter as an example of a marker polynucleotide sequence and the nptII gene from E. coli under control of the nos promoter as an example of a polynucleotide sequence of interest; pTDCs. This binary vector was used in Agrobacterium tumefaciens mediated transformation of Nicotiana tabacum, via a leaf-disc transformation procedure.

Using 4-methyltryptophan (4-mT) as selective compound it was found that explants of tobacco plants transformed with pTDCs survived selection, gave rise to shoot formation and could be regenerated into whole plants on a medium containing up to 0.5 mM 4-mT. Explants of tobacco plants that did not contain the pTDCs construct (control plants) turned pale and eventually died. Virtually no explants of the control plants escaped from selection.

To check for the presence of the polynucleotide sequence of interest the surviving shoots were transferred to a medium containing 100 mg/l kanamycin. All transferred shoots showed normal growth and rooting on this medium indicating that the plants did not only contain the marker but also the nptII gene. This was confirmed on Northern blots which showed that the mRNAs from both genes were present in the 4-mT resistant

cells.

These results exemplify that a tryptophan analogue can be used as selective compound in the selection of plants or plant cells having obtained a polynucleotide sequence of interest, using a gene encoding a tryptophan analogue converting activity as a marker. It should be understood that although the plant expressible nptII gene can be used as a selectable marker gene for plant transformation it was used as a typical plant expressible gene of interest. Thus, it will be appreciated by those of skill in the art that in principle any plant expressible gene, including those that are not selectable marker genes, can be introduced into a plant cell similar as illustrated for the npt gene in the this example. Examples of such plant expressible genes of interest have been referred to above together with the references where their isolation and characteristics were described.

Although the use of the tryptophan analogue converting activity as a marker has been illustrated in more detail for genetic transformation, those skilled in the art will appreciate that the selectable marker according to the invention can also be used in classical breeding and for the production of hybrid varieties and so forth.

All references cited in this specification are indicative of the level of skill in the arts to which the invention pertains. All publications, whether patents or otherwise, referred to previously or later in this specification are herein separately incorporated by reference.

The Examples given below are just given for purposes of enablement and do not intend in any way to limit the scope of the invention.

#### EXPERIMENTAL

##### Tryptophan decarboxylase assay

Tryptophan decarboxylase activity was determined according to Pennings E.J.M. et al., (1987) Anal. Biochem. 165, 133-136. Protein determinations were performed according to

Bradford, M.M. et al., (1976) Anal. Biochem. 72, 248.

Purification of TDC isolated from Catharanthus roseus cell suspension cultures

5 Cell suspensions of C. roseus were grown for 5 days on induction medium (Knobloch K.H. and Berlin J. (1980) Z. Naturforsch. 35c, 551), harvested, frozen in liquid nitrogen and either stored at -80°C or used immediately for purification of TDC. Partially purified TDC (estimated purity  
10 about 20%) was obtained after ammonium sulphate precipitation, anion exchange and size exclusion chromatography as described by Pennings, E.J.M. et al., (1989) Journal of Chromatography 483, 311-318). After size exclusion chromatography, fractions containing TDC activity  
15 were pooled. The fractions were adjusted to Laemmli sample buffer conditions and boiled for 5 min. The samples were subjected to preparative SDS PAA gel electrophoresis on 3 mm thick discontinuous gels consisting of a 3.75% stacking gel and a 10% separation gel according to Laemmli, U.K. et al.,  
20 (1970) Nature 227, 680-685. After electrophoresis, gels were stained for 90 min. in 10% acetic acid, 40% methanol, 0.1% coomassie brilliant blue R250 and destained for 60 min. in 10% acetic acid, 10% methanol. The 47kD TDC monomer band was sliced out of the gel and soaked in water. Electroelution of  
25 the TDC protein from the gel fragments was performed according to Hunkapillar M.W. et al., (1983) Methods in enzymology 91, 227-236). Recovery of the TDC protein after electrophoresis and electroelution as determined by analytical SDS PAA gel electrophoresis was estimated to be  
30 90%.

Preparation of antiserum against TDC

Eluate samples containing 150 µl of Freund's complete adjuvant (Gibco) were injected subcutaneously in two New  
35 Zealand white rabbits. Booster injections, eluate samples containing 75 µg of denatured TDC emulsified with 600 µl of Freund's incomplete adjuvant, were administered three times

at two-week intervals. The rabbits were bled two weeks after the last injection. Blood samples were left at room temperature for several hours and centrifuged at 2000 rpm for 30 minutes. The clear supernatant was harvested and stored at  
5 -20°C. Antibody titers were determined by Enzyme Linked Immunosorbent Assay (ELISA).

#### ELISA

Wells of a Dynatech microtiter plate were coated overnight  
10 at 4°C with 0.1 µg of purified denatured TDC in 100 µl 0.05 M carbonate buffer pH 9.6. After rinsing, plates were incubated for 1 hour with phosphate buffered saline (PBS: 140 mM NaCl, 20 mM Na-phosphate pH 7.4) containing 1% gelatin and 0.05% Tween 20 at 37°C and rinsed again. Antiserum diluted in  
15 PBS/gelatin/Tween was added and incubated for 2 hours at 37°C. The wells were rinsed again and goat anti-rabbit globulins conjugated with alkaline phosphatase (Sigma A8025), 1000 fold diluted in PBS/gelatin/Tween was added. Following incubation for 2 hours at 37°C and rinsing, 0.5 mg/ml of the  
20 substrate paranitrophenylphosphate dissolved in 10% diethanolamine pH 9.8 was added. The reaction was stopped by adding 1 volume of 1 N NaOH. The absorbance at 405 nm was measured in a Titertek multiscan photometer.

#### 25 Plant Material

##### A. Catharanthus roseus

Cell suspension cultures of C. roseus L. (G. Don) were grown in LS medium (Linsmayer et al., (1965) *Physiologia plantarum* 18, 100-127) containing 2 mg/l 1-naphthalene acetic  
30 acid (NAA), 0.2 mg/l kinetin (KIN) and 0.03% w/v sucrose at 27°C on a Kühner Lab-shaker with a shaking diameter of 5 cm at 95 rpm under a 12 hour light/dark regime. Subculturing was performed every 10-12 days by 10-fold dilution of the cells in fresh medium. Induction of TDC activity was achieved by  
35 transferring 10 days old cells to induction medium (IM) as described by Berlin et al. (Berlin J. et al., (1983) *Z. Naturforsch.* 38C, 346).

Hairy root cultures of C. roseus were subcultured every week in modified Gamborg B5 medium (Gamborg O.L. et al., (1968) Exp. Cell. Res. 50, 151-158). The concentration of macronutrients and the CaCl<sub>2</sub> concentration were lowered  
5 respectively four and two times.

Catharanthus seeds (Vinca rosea, variety Morning mist) were obtained from Kieft (Blokker, Holland), and grown in the greenhouse at 23°C under a 12 hour light/dark regime.

10 Nicotiana tabacum

Nicotiana tabacum, cv Petit Havanna SR1 plants were grown in vitro on solidified MS medium (Murashige, T. et al., (1962) Physiol. Plant. 15, 473-497) containing 30g/l sucrose at 27°C with 12 hours illumination each day.

15

DNA-methodology

DNA isolation, subcloning, restriction analyses and sequencing were performed using standard procedures well known to persons skilled in the art, vide e.g. Maniatis et al., 1982. Molecular Cloning: A Laboratory Manual (Cold  
20 Spring Harbor, NY: Cold Spring Harbor Laboratory).

Northern blot analysis

Total RNA from green tissues of in vitro plants was  
25 isolated according to Van Slogteren, G.M.S. et al., (1983) Plant Molecular Biology 2, 321-333. RNA was glyoxylated, electrophoresed on 1.5% agarose gels and transferred to Genescreen membranes using the capillary blot method. The cloned tdc cDNA was <sup>32</sup>P labeled with random primers (Prime-  
30 it kit, Stratagene) and hybridized to the blot in 5x SSPE, 50% formamide, 0.5% SDS at 42°C. After 60-65 hours, filters were washed in 0.1xSSPE, 5% SDS at 65°C for 15 min. and once in 0.5xSSPE at room temperature for 5 min. Hybridization was visualized by exposing the RNA blots at -80°C for 1-3 days to  
35 Fuji-RX films mounted on Kyokko-LHII intensifying screens.

DNA, RNA and protein sequencing

Deletions of the EcoRI inserts of pCCR2 and pCCR19 were generated from both 5' and 3' ends using the ExoIII/Mung-bean system (Promega). The resulting deletion constructs were completely sequenced by the dideoxy chain termination method (Sanger, F. et al., (1977) Proc. Natl. Acad. Sci. USA 74, 5463-5467). Both strands were sequenced over their entire length. RNA sequencing was performed according to Geliebter, J. et al., (1987) Focus 9:1, 5-8). Sequence data were analysed using the University of Wisconsin Genetics Computing Group programs.

Protein sequencing was performed at the Max Planck Institut für Molekulare Genetic in Berlin.

#### Tobacco leaf-disc transformation

The leaf-disc transformation procedure was essentially as described by Horsch et al., supra. Nicotiana tabacum SR1 leaf-discs were incubated for 20 minutes in 90 ml MS 10 medium (MS 10: MS medium containing 0.1 mg/l naphthalene acetic acid (NAA) and 1.0 mg/l benzylaminopurine (BAP)) supplemented with 10 ml of Agrobacterium tumefaciens strain LBA 4404 grown overnight in LC (Maniatis et al., 1982, supra), harbouring the binary vectors with the various DNA constructs. Leaf explants were blotted dry and placed upside down on MS 10 medium. After 48 hours, explants were transferred to MS 10 medium containing 100 mg/l cefotaxime, 100 mg/l vancomycin and 100 mg/l kanamycin or 0-1mM 4-methyl tryptophan for selection of transgenic shoots.

#### EXAMPLE 1

Isolation of a cDNA clone encoding tryptophan decarboxylase

##### A Construction of a lambda-qt11 expression cDNA library

Total RNA was isolated from a suspension culture of Catharanthus roseus cultured on induction medium for 24 hours. Poly A<sup>+</sup> RNA was isolated as described by van Slogteren et al. (1983), supra. with a minor modification; binding buffer was used to wash loaded oligo (dT)-cellulose columns.

- 21 -

First strand cDNA synthesis was as described by Maniatis et al. (1982), supra. Second strand synthesis was according to Gubler and Hoffman (1983) Gene 25, 263-269) with omission of DNA ligase and  $\beta$ -NAD. Phosphorylated EcoRI linkers  
5 (Pharmacia) were ligated to double stranded (ds) cDNA according to Maniatis et al., (1982), supra. Linked ds cDNA was EcoRI digested, size selected by chromatography on Sepharose CL-4B and cloned in the EcoRI site of lambda-gt11 (Promega). After packaging (Promega packaging mix) and  
10 infection of the host strain E. coli Y1090 (Promega, O.D.  $\approx 0.6$ , grown in LC containing 0.2% maltose and 10mM  $MgSO_4$ )  $2.32 \times 10^5$  pfu/ $\mu$ g lambda-gt11 were obtained of which 82% were recombinant. The cDNA library was amplified according to Huyng, T.V. et al., (1985) DNA Cloning, a practical approach  
15 1, 49-78.

#### B. Screening of the cDNA library

After amplification,  $2 \times 10^5$  plaques were screened with polyclonal antiserum raised against denatured TDC. Phages  
20 absorbed to Escherichia coli Y1090 were plated in 8 ml top-agarose on LC medium in 14,5 cm diameter petridishes and incubated at 37°C. A maximum of 20.000 plaques were plated on each petridish. After 3.5 hours (no plaques were visible), nitrocellulose filters (Schleicher and Schuell) saturated  
25 with 10mM IPTG (air-dried) were placed on top of the agarose. The plates were incubated for another 3.5 hours and placed overnight at 4°C. After marking the position with a needle and ink, filters were lifted from the agarose (now plaques were visible) and washed extensively in TBST (10mM Tris-HCl  
30 pH8.0, 150mM NaCl, 0.05% Tween 20) to remove agarose remnants.

To saturate nonspecific protein binding sites, filters were incubated for 30' in TBST containing 1% gelatin. The filters were transferred to a solution containing 1000 fold  
35 diluted TDC antiserum in TBST and incubated overnight at room temperature. The antiserum was preincubated with 0.5 mg/ml Y1090 protein extract to reduce the background produced by

anti E. coli antibodies. After rinsing the filters in TBST (three times for 15') incubation continued for 60' in 1:7500 diluted second antibody alkaline-phosphatase conjugate. Again the filters were rinsed in TBST followed by a color reaction, performed according to Promega (Protoblot Immunoscreening System, technical manual). This reaction was stopped by replacing the substrate solution with 10mM Tris, 1 mM EDTA pH 8.0.

10 C. Characterization and sequence determination of the isolated cDNA clones

Screening of about 200,000 initial transformants resulted in the isolation of 7 positive clones. Purification of the lambda phages and isolation of their insert revealed, that 5 clones contained an insert of about 1600 bp and 2 clones contained an insert of about 830 bp; both types of inserts did not cross hybridize. The inserts were subcloned in the EcoRI site of a bluescript SK vector (Stratagene) resulting in pCCR2 (ca. 1600 bp insert) and pCCR19 (ca. 830 bp insert). Northern blot analysis revealed, that the inserts of pCCR2 and pCCR19 correspond both with a mRNA of approximately 1700 nucleotides, a size expected for tdc mRNA.

Upon Northern blot analysis, it was observed that levels of mRNA hybridising to pCCR2 were raised in cell suspensions from Catharanthus roseus grown on induction medium as compared to cells grown in non-induction medium; no differences were observed using the pCCR19 insert as probe. This induction is in accordance with the de novo synthesis of tryptophan decarboxylase in cell suspensions of C. roseus as described by Noé, W. et al., (1985) Planta 166, 500-504). Hence, we concluded that the insert of pCCR2 could correspond with a tdc cDNA.

Both strands of the pCCR2 insert were sequenced using subclones and deletions generated by ExoIII and Mung bean nuclease digestions (Promega).

The pCCR2 insert contained an open reading frame lacking a startcodon, indicating that an incomplete cDNA clone had been



obtained. The missing sequences were determined by primer extension on poly A<sup>+</sup> RNA (See Experimental Part of this specification). The determined nucleotide sequence is given in SEQIDNO: 1. This sequence reveals two putative translation start codons; the ATG starting at position 60 (first ATG) and the ATG starting on position 90 (second ATG) as indicated in SEQIDNO: 1.

N-terminal sequence analysis of the purified 47kD TDC monomer revealed that the isolated protein starts with the amino acid sequence: Ser-Pro-Val-Gly-Glu-Phe-Lys-Pro-Leu, corresponding with nucleotide position 99 to 125 in SEQIDNO: 1. Since both ATG codons are in frame and we did not know whether the mRNA is translated from the first or the second ATG we decided to use the second ATG as translation start codon in our constructs.

To complete our tdc cDNA fragment we set out to synthesise an oligonucleotide encoding the missing amino acid residues spanning nucleotide position 90 to 125 (SEQIDNO: 1), flanked by a SalI and EcoRI restriction site, and an artificially introduced NcoI site. We finally obtained the oligonucleotide sequence as depicted in SEQIDNO: 2.

This oligonucleotide sequence contains a point mutation corresponding with position 93 in SEQIDNO: 1, creating a NcoI site; the point mutation changes codon 2 from TCC encoding a Serine residue into GCC encoding a Alanine residue. Due to an error in DNA synthesis also codon 10 (AAG) encoding a Lysine residue was changed into AAT encoding an Asparagine residue.

#### EXAMPLE 2

##### Construction of the binary vectors pBDH5, pTDCs and pTDCa

The wide host range expression vector pBDH5 was constructed by deleting the SalI restriction site from a Bin19 binary vector (Bevan, M. et al., (1984) Nuc. Acid Res. 12, 8711-8721) and inserting a 35S CaMV expression cassette from pDH51 (Pietrzak, M. et al., (1986) Nuc. Acid Res. 14, 5857-5868) as an EcoRI fragment (figure 1). The obtained construct in which the CaMV 35S promoter has the same

orientation as the nos promoter of the nptII gene (pBDH5) was used in further cloning procedures.

The synthetic SalI - EcoRI fragment depicted in SEQ ID NO: 2 was cloned in pIC20H (Marsch, J.L. et al., (1984) Gene 32, 481-485). The incomplete tdc cDNA fragment of pCCR2 was cloned as EcoRI fragment, using the EcoRI in the coding region starting at position 135 in SEQIDNO: 1, behind the synthetic SalI-EcoRI fragment, yielding pIST6 (Figure 1). The completed tdc cDNA was excised as SalI - XhoI fragment (vide SEQ ID NO: 3) and cloned in both orientations in the SalI site of the pBDH5 binary vector resulting in pTDCs (sense construct) and pTDCa (antisense construct) (figure 1). The binary vectors were electroporated to Agrobacterium tumefaciens strain LBA 4404 as described by Mattonovich, D. et al., (1989) Nuc. Acid Res. 17, 6747) resulting in LBA4404 (pBDH5), LBA4404 (pTDCs) and LBA4404 (pTDCa) respectively.

### EXAMPLE 3

#### Generation of tdc transgenic plants: Kanamycin selection

20 Leaf-disc transformation of Nicotiana tabacum and subsequent selection on 100 mg/l kanamycin resulted in transgenic plants harbouring T-DNA (transferred DNA) derived from pBDH5 (empty vector), pTDCs (sense construct) and pTDCa (antisense construct) tdc gene constructs, hereinafter referred to as pBDH5, pTDCs and pTDCa respectively. Levels of tdc mRNA were determined in green tissues of the obtained transgenic plants. Plants harbouring pTDCs displayed at least a 10-fold variation in tdc mRNA accumulation between the best (tobacco line E) and the worst expressors (lines A and G) (figure 2). Longer exposure times of the blot clearly show the presence of tdc mRNA in the plants A and G. Four out of ten plants (B, C, D and F) had an intermediate level of tdc mRNA, while the same number of plants showed a strong expression (E, H, I and J). No tdc mRNA could be detected in 35 plants harbouring the pBDH5 and pTDCa plasmids.

Of 5 plants (A, B, E, F and J) harbouring the pTDCs constructs TDC activities were determined (Table 1). These

- 25 -

data show that the overexpression of tdc cDNA in tobacco tissues results in TDC activity, which is normally not present in tobacco plants. Plant E showing the highest tdc mRNA level also showed the highest TDC enzyme activity.

5

10

Table 1: TDC activities in tdc transgenic Nicotiana tabacum plants.

15

TDC activity  
pkat/mg protein

20	SENSE	A	4
		B	5
		E	69
		F	5
		J	19
	ANTISENSE		0
	VECTOR		0

25

Table 1: TDC activities, as determined by HPLC analysis, in pBDH5 (vector), pTDCa (antisense) or pTDCs (sense) transformed N. tabacum plants.

30

#### EXAMPLE 4

#### Sensitivity of leaf explants from tdc transformed tobacco plants to 4-methyl tryptophan

To determine the sensitivity of the tdc transgenic Nicotiana tabacum plants for 4-methyl tryptophan, leaf  
35 explants were incubated on shooting medium (MS 10) containing 0, 0.05, 0.1, 0.5 and 1 mM 4-methyl tryptophan. Explants of three tdc transgenic tobacco plants were tested (pTDCs; A, C

and I) displaying low, intermediate and high tdc transcript levels respectively. As a control, leaf explants from pBDH5 transformed plants were tested. After 6 weeks, shooting of the explants was scored relative to the amount of shooting obtained on medium without 4-methyl tryptophan.

5 Explants from the pTDCs-I (high tdc transcript level) transformed plants gave rise to shoot formation on medium containing up to 0.5 mM 4-mT although some reduction in shooting frequency was observed at this concentration (figure

10 2). Explants of pTDCs-A (low tdc transcript level) gave rise to shoot formation up to 0.1 mM 4-mT. Higher concentrations of 4-mT resulted in reduced or absence of shooting. The plant with an intermediate tdc mRNA expression (pTDCs-C) also showed intermediate sensitivity to 4-mT. From our

15 experiments we observed that there seems to be a better correlation between tdc mRNA levels and sensitivity to 4-mT as opposed to TDC enzyme levels and sensitivity to 4-mT. We therefore concluded that the enzyme assay is not very sensitive; only large differences in TDC enzyme levels allow

20 to predict differences in sensitivity to 4-mT.

When cultured on 1mM 4-mT, none of the explants harbouring the tdc sense construct gave rise to substantial shoot formation.

Nearly all explants of the pBDH5 transformed plants turned

25 pale and died on medium containing 4-mT. Some explants cultured on 0.05 and 0.1 mM 4-mT gave rise to a few "escape" shoots. Those shoots predominantly arose from explants containing main-nerve tissue.

30

#### EXAMPLE 5

##### Generation of transgenic plants using tdc as marker and selecting on 4-methyl tryptophan

Based on the shooting capacity of tdc transgenic leaf-discs on 4-mT containing MS 10 medium, an experiment was

35 performed using tdc as selection marker in Nicotiana tabacum leaf-disc transformation. Leaf explants of N. tabacum SR1 were cocultivated with LBA 4404 containing the tdc/nptII

- 27 -

constructs. After 48 hours leaf-discs were incubated on MS 10 medium containing 0.1 mM 4-mT. After 6 weeks the explants were scored for shoot formation.

Leaf explants incubated with LBA 4404 (pTDCs) gave rise to 5 abundant shoot formation on medium containing up to 0.1 mM 4-mT (figure 4). Explants cultured on medium containing 0.5 mM 4-mT showed a reduced and delayed shooting response. No shoot formation was observed on medium containing 1 mM 4-mT.

Control plates, containing explants treated with LBA4404 10 (pTDCa) (antisense), LBA4404 (pBDH5) or leaf-discs not treated with Agrobacterium at all, did not give rise to substantial shoot formation. Some "escape" shoots were formed out of main nerve tissue from explants cultured on 0.05 and 0.1 mM 4-mT as expected from our data.

15 All the obtained shoots from leaf explants cultured on MS 10 medium supplemented with 0.1 mM 4-mT were excised and grown on MS medium containing 0.1 mM 4-mT. On further growth, all plants derived from leaf-disc transformation without Agrobacterium or with LBA 4404 containing pBDH5 and pTDCa 20 turned pale and died. Of 30 transgenic shoots derived from the transformation of leaf-discs with LBA 4404 containing pTDCs, 24 shoots (80%) showed normal growth on medium containing 0.1 mM 4-mT. Six shoots died on this medium, which is in accordance with the number of escape shoots formed on 25 the control plates. In our hands, these data were comparable to those obtained with leaf-disc transformation experiments using kanamycin as selective agent.

To establish whether the nptII gene was transferred to the plant cells, the surviving shoots were transferred to medium 30 containing 100 mg/l kanamycin. All transferred shoots showed normal growth and rooting on this medium suggesting the plants to be transformed with both the tdc gene and the nptII gene. Transcript levels of both genes were determined in 6 shoots by Northern blot analysis (figure 4). It appeared that 35 the nptII gene was transferred and expressed to the plant.

From these data we conclude that 4-mT can be used as a selective agent for the efficient selection of transformed

plant cells using the tdc gene as a marker gene.

## SEQUENCE LISTING

- 5 INFORMATION FOR SEQ ID NO: 1:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1731 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 10 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: cDNA to mRNA  
 (iii) ORIGINAL SOURCE:  
 (A) ORGANISM: Catharanthus roseus  
 (B) STRAIN: G. don  
 15 (D) DEVELOPMENTAL STAGE: Suspension cells  
 (iv) IMMEDIATE SOURCE:  
 (A) LIBRARY: lambda gt11  
 (B) CLONE: pCCR2  
 (v) FEATURE:  
 20 (A) NAME/KEY: CDS  
 (B) LOCATION: 60..1559  
 (vi) FEATURE:  
 (A) NAME/KEY: polyA\_signal  
 (B) LOCATION: 1708..1713  
 25 (vii) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

CTCTCTCTAA GACTTTCTCT CTCTACACAT ACACCTACAC CAGAAAAAAG AAAAAAATA      59
30 ATG GGC AGC ATT GAT TCA ACA AAT GTA GCC ATG TCC AAT TCT CCA GTT      107
   Met Gly Ser Ile Asp Ser Thr Asn Val Ala Met Ser Asn Ser Pro Val
   1           5           10           15
   GGA GAA TTT AAG CCA CTT GAA GCT GAG GAA TTC CGA AAA CAA GCC CAT      155
35 Gly Glu Phe Lys Pro Leu Glu Ala Glu Glu Phe Arg Lys Gln Ala His
   20           25           30
   CGT ATG GTA GAT TTC ATA GCC GAT TAT TAC AAA AAT GTG GAA ACA TAT      203
40 Arg Met Val Asp Phe Ile Ala Asp Tyr Tyr Lys Asn Val Glu Thr Tyr
   35           40           45
   CCG GTC CTT AGC GAA GTC GAA CCT GGA TAT CTC CGA AAA CGT ATC CCC      251
   Pro Val Leu Ser Glu Val Glu Pro Gly Tyr Leu Arg Lys Arg Ile Pro
   50           55           60
   GAA ACC GCT CCT TAC CTC CCC GAA CCA CTT GAC GAC ATC ATG AAA GAT      299
45 Glu Thr Ala Pro Tyr Leu Pro Glu Pro Leu Asp Asp Ile Met Lys Asp
   65           70           75           80
   ATT CAG AAG GAT ATT ATC CCA GGA ATG ACA AAT TGG ATG AGC CCT AAT      347
50 Ile Gln Lys Asp Ile Ile Pro Gly Met Thr Asn Trp Met Ser Pro Asn
   85           90           95
   TTT TAT GCA TTT TTT OCT GCC ACT GTT AGT TCA GCT GCC TTT TTA GGA      395

```

- 29 -

	Phe	Tyr	Ala	Phe	Phe	Pro	Ala	Thr	Val	Ser	Ser	Ala	Ala	Phe	Leu	Gly	
				100					105					110			
5	GAA	ATG	TTG	TCT	ACT	GCC	CTA	AAT	TCA	GTA	GGC	TTT	ACT	TGG	GTT	TCT	443
	Glu	Met		Leu	Ser	Thr	Ala	Leu	Asn	Ser	Val	Gly	Phe	Thr	Trp	Val	Ser
				115					120					125			
10	TCA	CCA	GCC	GCC	ACC	GAA	TTA	GAA	ATG	ATT	GTT	ATG	GAT	TGG	TTG	GCT	491
	Ser	Pro	Ala	Ala	Thr	Glu	Leu	Glu	Met	Ile	Val	Met	Asp	Trp	Leu	Ala	
			130					135					140				
15	CAG	ATC	CTT	AAA	CTC	CCC	AAA	TCT	TTC	ATG	TTT	TCA	GGT	ACC	GGT	GGC	539
	Gln	Ile	Leu	Lys	Leu	Pro	Lys	Ser	Phe	Met	Phe	Ser	Gly	Thr	Gly	Gly	
						150					155					160	
	GGC	GTC	ATC	CAA	AAC	ACC	ACT	AGC	GAG	TCC	ATT	CTT	TGT	ACA	ATC	ATT	587
	Gly	Val	Ile	Gln	Asn	Thr	Thr	Ser	Glu	Ser	Ile	Leu	Cys	Thr	Ile	Ile	
					165					170							
20	GCC	GCC	CGG	GAA	AGG	GCC	CTG	GAG	AAG	CTC	GGT	CCC	GAT	AGT	ATT	GGA	635
	Ala	Ala	Arg	Glu	Arg	Ala	Leu	Glu	Lys	Leu	Gly	Pro	Asp	Ser	Ile	Gly	
				180					185					190			
25	AAA	CTT	GTC	TGT	TAC	GGA	TCC	GAT	CAA	ACC	CAT	ACC	ATG	TTC	CCC	AAA	683
	Lys	Leu	Val	Cys	Tyr	Gly	Ser	Asp	Gln	Thr	His	Thr	Met	Phe	Pro	Lys	
			195					200					205				
30	ACT	TGC	AAA	TTG	GCG	GGA	ATT	TAT	COG	AAT	AAT	ATT	AGG	TTA	ATA	OCT	731
	Thr	Cys	Lys	Leu	Ala	Gly	Ile	Tyr	Pro	Asn	Asn	Ile	Arg	Leu	Ile	Pro	
			210				215					220					
35	ACG	ACC	GTC	GAA	ACG	GAT	TTC	GGC	ATC	TCA	CCT	CAA	GTT	CTA	CGA	AAA	779
	Thr	Thr	Val	Glu	Thr	Asp	Phe	Gly	Ile	Ser	Pro	Gln	Val	Leu	Arg	Lys	
			225			230					235					240	
	ATG	GTC	GAG	GAT	GAC	GTG	GCG	GCC	GGA	TAT	GTA	COG	CTG	TTC	TTA	TGC	827
	Met	Val	Glu	Asp	Asp	Val	Ala	Ala	Gly	Tyr	Val	Pro	Leu	Phe	Leu	Cys	
					245				250						255		
40	GCT	ACC	CTG	GGT	ACC	ACC	TGG	ACC	ACG	GCT	ACC	GAT	CCT	GTG	GAC	TCA	875
	Ala	Thr	Leu	Gly	Thr	Thr	Ser	Thr	Thr	Ala	Thr	Asp	Pro	Val	Asp	Ser	
				260					265					270			
45	CTT	TCT	GAA	ATC	GCT	AAC	GAG	TTT	GGT	ATT	TGG	ATC	CAC	GTG	GAT	GCT	923
	Leu	Ser	Glu	Ile	Ala	Asn	Glu	Phe	Gly	Ile	Trp	Ile	His	Val	Asp	Ala	
			275					280					285				
50	GCT	TAT	GCG	GGA	AGC	GCC	TGT	ATA	TCT	CCC	GAG	TTT	AGA	CAT	TAC	TTG	971
	Ala	Tyr	Ala	Gly	Ser	Ala	Cys	Ile	Cys	Pro	Glu	Phe	Arg	His	Tyr	Leu	
		290					295					300					
55	GAT	GGA	ATC	GAA	CGA	GTT	GAC	TCA	CTG	AGT	CTG	AGT	CCA	CAC	AAA	TGG	1019
	Asp	Gly	Ile	Glu	Arg	Val	Asp	Ser	Leu	Ser	Leu	Ser	Pro	His	Lys	Trp	
		305				310					315					320	

WO 93/06220

- 30 -

	CTA CTC GCT TAC TTA GAT TGC ACT TGC TTG TGG GTC AAG CAA CCA CAT Leu Leu Ala Tyr Leu Asp Cys Thr Cys Leu Trp Val Lys Gln Pro His 325 330 335	1067
5	TTG TTA CTA AGG GCA CTC ACT ACG AAT CCT GAG TAT TTA AAA AAT AAA Leu Leu Leu Arg Ala Leu Thr Thr Asn Pro Glu Tyr Leu Lys Asn Lys 340 345 350	1115
10	CAG AGT GAT TTA GAC AAA GTT GTG GAC TTC AAA AAT TGG CAA ATC GCA Gln Ser Asp Leu Asp Lys Val Val Asp Phe Lys Asn Trp Gln Ile Ala 355 360 365	1163
15	ACG GGA CGA AAA TTT CGG TCG CTG AAA CTT TGG CTC ATT TTA CGT AGC Thr Gly Arg Lys Phe Arg Ser Leu Lys Leu Trp Leu Ile Leu Arg Ser 370 375 380	1211
	TAT GGA GTT GTT AAT TTA CAG AGT CAT ATT CGT TCT GAC GTC GCA ATG Tyr Gly Val Val Asn Leu Gln Ser His Ile Arg Ser Asp Val Ala Met 385 390 395 400	1259
20	GGC AAA ATG TTC GAA GAA TGG GTT AGA TCA GAC TCC AGA TTC GAA ATT Gly Lys Met Phe Glu Glu Trp Val Arg Ser Asp Ser Arg Phe Glu Ile 405 410 415	1307
25	GIG GTA CCG AGA AAC TTT TCT CTT GTT TGT TTT AGA TTA AAA CCT GAC Val Val Pro Arg Asn Phe Ser Leu Val Cys Phe Arg Leu Lys Pro Asp 420 425 430	1355
30	GTT TCG AGT TTA CAT GTA GAA GAA GTG AAT AAG AAA CTT TTG GAC ATG Val Ser Ser Leu His Val Glu Glu Val Asn Lys Lys Leu Leu Asp Met 435 440 445	1403
35	CTT AAC TCG ACG GGA CGA GTT TAT ATG ACT CAT ACT ATT GTG GGA GGC Leu Asn Ser Thr Gly Arg Val Tyr Met Thr His Thr Ile Val Gly Gly 450 455 460	1451
	ATA TAC ATG CTA AGA CTG GCT GTT GGC TCA TCG CTA ACT GAA GAA CAT Ile Tyr Met Leu Arg Leu Ala Val Gly Ser Ser Leu Thr Glu Glu His 465 470 475 480	1499
40	CAT GTA CGC CGT GTT TGG GAT TTG ATT CAA AAA TTA ACC GAT GAT TTG His Val Arg Arg Val Trp Asp Leu Ile Gln Lys Leu Thr Asp Asp Leu 485 490 495	1547
45	CTC AAA GAA GCT TGATGAATAA GTAAGGTTT TTTTTPAATT TTTTTTAA Leu Lys Glu Ala 500	1599
50	TTTTATATTT GCTGATTGTT TGAAGAGTTT AAAATAAAG TGATTGTAA AGGTTTATTG TACTCAACA ATCATGCAAT TAATTATATG TATTAATTAT GACATGAGAA TAAATAGAA TTTTGTGTGTG CA.	1659 1719 1731



- 31 -

## INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 61 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: both  
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: YES
- (iv) ORIGINAL SOURCE:  
 (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide
- (v) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 11..61
- (vi) FEATURE:  
 (A) NAME/KEY: misc\_feature  
 (B) LOCATION: 1..6  
 (D) OTHER INFORMATION: /label= SalI
- (vii) FEATURE:  
 (A) NAME/KEY: misc\_feature  
 (B) LOCATION: 56..61  
 (D) OTHER INFORMATION: /label= EcoRI
- (viii) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

25 GTCGACAGCC ATG GCC AAT TCT CCA GTT GGA GAA TTT AAT CCA CTT GAA 49  
 Met Ala Asn Ser Pro Val Gly Glu Phe Asn Pro Leu Glu  
 1 5 10

GCT GAG GAA TTC 61  
 30 Ala Glu Glu Phe  
 15

## INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1652 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: both
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: YES
- (iv) ORIGINAL SOURCE:  
 (A) ORGANISM: Catharanthus roseus  
 (B) STRAIN: G. don  
 (D) DEVELOPMENTAL STAGE: Suspension cells
- (v) IMMEDIATE SOURCE:  
 (A) LIBRARY: lambda gt11  
 (B) CLONE: pCCR2
- (vi) FEATURE:  
 (A) NAME/KEY: misc\_feature  
 (B) LOCATION: 1..6  
 (D) OTHER INFORMATION: /label= SalI
- (vii) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 11..1480

## (viii) FEATURE:

(A) NAME/KEY: misc\_feature

(B) LOCATION: 56..61

(D) OTHER INFORMATION: /label= EcoRI

## 5 (ix) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	GTCGACAGCC ATG GCC AAT TCT CCA GTT GGA GAA TTT AAT CCA CTT GAA	49
	Met Ala Asn Ser Pro Val Gly Glu Phe Asn Pro Leu Glu	
	1 5 10	
10	GCT GAG GAA TTC CGA AAA CAA GCC CAT CGT ATG GTA GAT TTC ATA GCC	97
	Ala Glu Glu Phe Arg Lys Gln Ala His Arg Met Val Asp Phe Ile Ala	
	15 20 25	
15	GAT TAT TAC AAA AAT GTG GAA ACA TAT CCG GTC CTT AGC GAA GTC GAA	145
	Asp Tyr Tyr Lys Asn Val Glu Thr Tyr Pro Val Leu Ser Glu Val Glu	
	30 35 40 45	
20	CCT GGA TAT CTC CGA AAA CGT ATC CCC GAA ACC GCT CCT TAC CTC CCC	193
	Pro Gly Tyr Leu Arg Lys Arg Ile Pro Glu Thr Ala Pro Tyr Leu Pro	
	50 55 60	
25	GAA CCA CTT GAC GAC ATC ATG AAA GAT ATT CAG AAG GAT ATT ATC CCA	241
	Glu Pro Leu Asp Asp Ile Met Lys Asp Ile Gln Lys Asp Ile Ile Pro	
	65 70 75	
30	GGA ATG ACA AAT TGG ATG AGC CCT AAT TTT TAT GCA TTT TTT CCT GCC	289
	Gly Met Thr Asn Trp Met Ser Pro Asn Phe Tyr Ala Phe Phe Pro Ala	
	80 85 90	
35	ACT GTT AGT TCA GCT GCC TTT TTA GGA GAA ATG TTG TCT ACT GCC CTA	337
	Thr Val Ser Ser Ala Ala Phe Leu Gly Glu Met Leu Ser Thr Ala Leu	
	95 100 105	
40	AAT TCA GTA GGC TTT ACT TGG GTT TCT TCA CCA GCC GCC ACC GAA TTA	385
	Asn Ser Val Gly Phe Thr Trp Val Ser Ser Pro Ala Ala Thr Glu Leu	
	110 115 120 125	
45	GAA ATG ATT GTT ATG GAT TGG TTG GCT CAG ATC CTT AAA CTC CCC AAA	433
	Glu Met Ile Val Met Asp Trp Leu Ala Gln Ile Leu Lys Leu Pro Lys	
	130 135 140	
50	TCT TTC ATG TTT TCA GGT ACC GGT GGC GGC GTC ATC CAA AAC ACC ACT	481
	Ser Phe Met Phe Ser Gly Thr Gly Gly Gly Val Ile Gln Asn Thr Thr	
	145 150 155	
55	AGC GAG TCC ATT CTT TGT ACA ATC ATT GCC GCC CGG GAA AGG GCC CTG	529
	Ser Glu Ser Ile Leu Cys Thr Ile Ile Ala Ala Arg Glu Arg Ala Leu	
	160 165 170	
60	GAG AAG CTC GGT CCC GAT AGT ATT GGA AAA CTT GTC TGT TAC GGA TCC	577
	Glu Lys Leu Gly Pro Asp Ser Ile Gly Lys Leu Val Cys Tyr Gly Ser	
	175 180 185	
65	GAT CAA ACC CAT ACC ATG TTC CCC AAA ACT TGC AAA TTG GCG GGA ATT	625

5 TAT CCG AAT AAT ATT AGG TTA ATA CCT ACG ACC GTC GAA ACG GAT TTC 673  
Tyr Pro Asn Asn Ile Arg Leu Ile Pro Thr Thr Val Glu Thr Asp Phe  
210 215 220

10 GGC ATC TCA CCT CAA GTT CTA CGA AAA ATG GTC GAG GAT GAC GTG GCG 721  
Gly Ile Ser Pro Gln Val Leu Arg Lys Met Val Glu Asp Asp Val Ala  
225 230 235

GCC GGA TAT GTA CCG CTG TTC TTA TGC GCT ACC CTG GGT ACC ACC TGG 769  
Ala Gly Tyr Val Pro Leu Phe Leu Cys Ala Thr Leu Gly Thr Thr Ser  
240 245 250

ACC ACG GCT ACC GAT CCT GTG GAC TCA CTT TCT GAA ATC GCT AAC GAG 817  
Thr Thr Ala Thr Asp Pro Val Asp Ser Leu Ser Glu Ile Ala Asn Glu  
255 260 265

20 TTT GGT ATT TGG ATC CAC GTG GAT GCT GCT TAT GCG GGA AGC GCC TGT 865  
Phe Gly Ile Trp Ile His Val Asp Ala Ala Tyr Ala Gly Ser Ala Cys  
270 275 280 285

ATA TGT CCC GAG TTT AGA CAT TAC TTG GAT GGA ATC GAA CGA GTT GAC 913  
25 Ile Cys Pro Glu Phe Arg His Tyr Leu Asp Gly Ile Glu Arg Val Asp  
          290                        295                               300

30 TCA CTG AGT CTG AGT CCA CAC AAA TGG CTA CTC GCT TAC TTA GAT TGC 961  
Ser Leu Ser Leu Ser Pro His Lys Trp Leu Leu Ala Tyr Leu Asp Cys  
305 310 315

ACT TGC TTG TGG GTC AAG CAA CCA CAT TTG TTA CTA AGG GCA CTC ACT 1009  
Thr Cys Leu Trp Val Lys Gln Pro His Leu Leu Leu Arg Ala Leu Thr  
320 325 330

ACG AAT OCT GAG TAT TTA AAA AAT AAA CAG AGT GAT TTA GAC AAA GTT 1057  
Thr Asn Pro Glu Tyr Leu Lys Asn Lys Gln Ser Asp Leu Asp Lys Val  
335 340 345

40 GTG GAC TTC AAA AAT TGG CAA ATC GCA ACG GGA CGA AAA TTT CGG TCG 1105  
Val Asp Phe Lys Asn Trp Gln Ile Ala Thr Gly Arg Lys Phe Arg Ser  
350 355 360 365

CTG AAA CTT TGG CTC ATT TTA CGT AGC TAT GGA GTT GTT AAT TTA CAG      1153  
45 Leu Lys Leu Trp Leu Ile Leu Arg Ser Tyr Gly Val Val Asn Leu Gln  
                370                         375                         380

AGT CAT ATT CGT TCT GAC GTC GCA ATG GGC AAA ATG TTC GAA GAA TGG 1201  
Ser His Ile Arg Ser Asp Val Ala Met Gly Lys Met Phe Glu Glu Trp  
50 385 390 395

GTT AGA TCA GAC TCC AGA TTC GAA ATT GTG GTA CCG AGA AAC TTT TCT 1249  
Val Arg Ser Asp Ser Arg Phe Glu Ile Val Val Pro Arg Asn Phe Ser  
400 405 410

	CTT GTT TGT TTT AGA TTA AAA CCT GAC GTT TOG AGT TTA CAT GTA GAA	1297
	Leu Val Cys Phe Arg Leu Lys Pro Asp Val Ser Ser Leu His Val Glu	
	415 420 425	
5	GAA GTG AAT AAG AAA CTT TTG GAC ATG CTT AAC TOG ACG GGA CGA GTT	1345
	Glu Val Asn Lys Lys Leu Leu Asp Met Leu Asn Ser Thr Gly Arg Val	
	430 435 440 445	
10	TAT ATG ACT CAT ACT ATT GTG GGA GGC ATA TAC ATG CTA AGA CTG GCT	1393
	Tyr Met Thr His Thr Ile Val Gly Gly Ile Tyr Met Leu Arg Leu Ala	
	450 455 460	
15	GTT GGC TCA TOG CTA ACT GAA GAA CAT CAT GTA CGC CGT GTT TGG GAT	1441
	Val Gly Ser Ser Leu Thr Glu Glu His His Val Arg Arg Val Trp Asp	
	465 470 475	
	TTG ATT CAA AAA TTA ACC GAT GAT TTG CTC AAA GAA GCT TGATGAATAA	1490
	Leu Ile Gln Lys Leu Thr Asp Asp Leu Leu Lys Glu Ala	
	480 485 490	
20	GTAAAGGGTTT TTTTAAATT TTTTAAATAA TTTTATATTT GCTGATIGTT TGAAGAGTTT	1550
	AAAAATAAAG TGATTGTAA AGGTTTATIG TACTCAAACA ATCATGCAAT TAATTATATG	1610
25	TATTAATTAT GACATGAGAA TAAATAGAA TTTGTGTGTG CA	1652

- 35 -

CLAIMS

1. A method for the selection of transformed plant cells, comprising the steps of:
- 5 i) transforming plant cells with a recombinant polynucleotide comprising a plant expressible gene encoding a tryptophan analogue converting activity,
- ii) culturing said plant cells, or growing plant material comprising said plant cells, in the presence of a selective amount of a tryptophan analogue deleterious to non-
- 10 transformed plant cells, under conditions that allow for the manifestation of said deleterious effect.
2. The method of claim 1, wherein said plant expressible gene encoding a tryptophan analogue converting
- 15 activity is a plant expressible tryptophan decarboxylase gene.
3. The method of claim 2, wherein the said tryptophan decarboxylase gene is the tdc gene from Catharanthus roseus
- 20 or a functional derivative thereof.
4. The method of claim 3, wherein said decarboxylase gene is under the control of the CamV 35S promoter.
- 25 5. The method of anyone of the claims 1 to 4, wherein said recombinant polynucleotide further comprises a polynucleotide sequence of interest.
6. The method of claim 5, wherein said polynucleotide
- 30 sequence of interest is a plant expressible gene which gives rise to fungal resistance, insect resistance, nematode resistance, virus resistance, altered carbohydrate composition, altered oil composition, altered amino acid composition, male-sterility, modified flower color, modified
- 35 fruit ripening, salt resistance, herbicide resistance, antibiotic resistance, production of a secondary metabolite, production of a pharmaceutical protein, or production of an

enzyme that can be used in an industrial process.

7. The method of any one of the claims 1 to 6, wherein the said tryptophan analogue is 4-methyltryptophan.

5

8. A plant cell obtained by a method of any one of the claims 1 to 7.

9. Plant material harbouring a cell of claim 8.

10

10. Plant material obtained by growing a plant cell of claim 8.

15

11. A plant part harbouring a cell according to claim 8, which part is selected from the group consisting of bulbs, flowers, fruits, hairy roots, leaves, microtubers, pollen, roots, seeds, stalks and tubers.

20

12. A plant regenerated from a cell of claim 8.

13. A plant part derived from a plant according to claim 12, which part is selected from the group consisting of bulbs, flowers, fruits, hairy roots, leaves, microtubers, pollen, roots, seeds, stalks and tubers.

25

14. A product obtained after the processing of a plant part of claim 13.

30

15. Use of a tryptophan analogue for the selection of a transformed plant cell.

35

16. Use of a plant expressible gene encoding an enzyme having a tryptophan analogue converting activity as a marker gene for the selection of transformed plant cells.

17. A method for obtaining a transformed plant comprising the steps of:

- 37 -

- i) transforming plant cells with a polynucleotide sequence comprising a plant expressible gene encoding a tryptophan analogue converting activity,
- ii) culturing said plant cells, or growing plant material comprising said plant cells, in the presence of a selective amount of a tryptophan analogue deleterious to non-transformed plant cells, under conditions that allow for the manifestation of said deleterious effect,
- iii) regenerating surviving cells of step ii) into a plant,
- iv) identifying a transformed plant.

18. The method of claim 17, wherein said plant expressible gene encoding a tryptophan analogue converting activity is a plant expressible tryptophan decarboxylase gene.

19. The method of claim 18, wherein the said tryptophan decarboxylase gene is the tdc gene from Catharanthus roseus or a functional derivative thereof.

20. The method of anyone of the claims 17 to 19, wherein said recombinant polynucleotide further comprises a polynucleotide sequence of interest.

21. The method of claim 20, wherein said polynucleotide sequence of interest is a plant expressible gene which gives rise to fungal resistance, insect resistance, nematode resistance, virus resistance, altered carbohydrate composition, altered oil composition, altered amino acid composition, male-sterility, modified flower color, modified fruit ripening, salt resistance, herbicide resistance, antibiotic resistance, production of a secondary metabolite, production of a pharmaceutical protein, or production of an enzyme that can be used in an industrial process.

22. The plant obtained with a method of any one of the claims 17 to 21.

23. Progeny plants obtained after sexually or asexually propagating a plant of claim 12 or 22.
- 5 24. A recombinant polynucleotide which can be used for the transformation of plant cells and subsequent selection of transformed plant cells, comprising a plant expressible gene encoding a tryptophan analogue converting activity.
- 10 25. The recombinant polynucleotide of claim 24, which further comprises a polynucleotide sequence of interest, with the proviso that said polynucleotide sequence of interest is not a plant expressible nptII gene.
- 15 26. The recombinant polynucleotide of claim 24, with the proviso that said polynucleotide sequence of interest is not known as a selectable marker gene for use in the transformation of plants.
- 20 27. The recombinant polynucleotide of claim 26, wherein the polynucleotide sequence of interest comprises a plant expressible gene which gives rise to fungal resistance, insect resistance, nematode resistance, virus resistance, altered carbohydrate composition, altered oil composition, 25 altered amino acid composition, male-sterility, modified flower color, modified fruit ripening, salt resistance, production of a secondary metabolite, production of a pharmaceutical protein or production of an industrial enzyme.
- 30 28. A recombinant plant DNA genome containing a copy of the recombinant polynucleotide of any one of the claims 24 to 27.
- 35 29. A plant or plant cell containing the recombinant plant DNA genome of claim 28.
30. A substantially pure DNA molecule which comprises



the nucleotide sequence represented in SEQIDNO: 2.

1/6




FIGURE 1

2/6




FIGURE 1 (CONTINUED)

3/6




FIGURE 2

4/6




FIGURE 3

5/6




FIGURE 4

6/6




FIGURE 5

## INTERNATIONAL SEARCH REPORT

PCT/EP 92/02175

International Application No

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5	C12N15/82; A01H5/00	C12N15/60; C12N5/10; A01H1/02
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	C12N ;	A01H
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	PLANT PHYSIOLOGY. vol. 94, no. 3, November 1990, ROCKVILLE, MD, USA. pages 1410 - 1413 SONGSTAD, D.O., ET AL. 'High levels of tryptamine accumulation in transgenic tobacco expressing tryptophan decarboxylase' cited in the application see the whole document	7-14, 22-24, 28-29
Y	---	1-5,7, 16-20
	---	-/--
<p><sup>*</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
11 DECEMBER 1992		18. 12. 92
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer MADDOX A.O.



III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	<p>BIOLOGICAL ABSTRACTS vol. 78  , 1984, Philadelphia, PA, US;  abstract no. 6552,  SASSE, F., ET AL. 'Selection of cell lines  of Catharanthus roseus with increased  tryptophan decarboxylase activity'  cited in the application  see abstract  &amp; Z. NATURFORSCH. SECT. C BIOSCI.  vol. 38, 1983, NO.11/12  pages 916 - 922</p>	1-5,7, 16-20
O,X	<p>---  J. CELL. BIOCHEM. SUPPL., MEETING HELD  JAN. 10-17, 1991.  vol. 15A, 1991,  page 70  GODDIJN, O.D.M., ET AL. 'Cloning and  regulation of the tryptophan decarboxylase  gene from Catharanthus roseus'  see abstract A320</p>	7-14, 22-24, 28,29
X	<p>---  EP,A,0 174 791 (MOLECULAR GENETICS)  19 March 1986  see page 20 - page 25</p>	15
A	<p>---  PROCEEDINGS OF THE NATIONAL ACADEMY OF  SCIENCES OF USA  vol. 86, April 1989, WASHINGTON US  pages 2582 - 2586  DE LUCA, V., ET AL. 'Molecular cloning and  analysis of cDNA encoding a plant  tryptophan decarboxylase: Comparison with  animal dopa decarboxylases'  see figure 2</p>	30

EP 9202175  
SA 64335

The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 11/12/92

Patent document cited in search report	Publication date	Patent family number(s)	Publication date
EP-A-0174791	19-03-86	US-A- 4581847	15-04-86
		US-A- 4642411	10-02-87
-----			

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**This Page Blank (uspto)**